AAN 2021 Poster Picks – Day 3
AAN 2021 Poster Picks – Day 2
Poster 033 – Motor Impairment in Multiple Sclerosis: Analysis from the North American Registry for Care and Research in Multiple Sclerosis (NARCRMS)
Kottil W. Rammohan, MD
Objective: 9-hole peg test (9-HPT) and 25-foot walk (25-FW) function. Read More
The trend to the early use of higher-efficacy disease-modifying therapies (DMT) in the management of MS was put on pause during the pandemic due to concerns about the effects of these agents on the immune response to SARS-CoV-2 and, latterly, to COVID-19 vaccination. However, as the pandemic dragged on, it became impractical to interrupt or delay treatment, and current DMT recommendations now emphasize that the risks of undertreated MS outweigh the possible risks of COVID, especially in a younger population. Read More
Ofatumumab (Kesimpta), a new anti-CD20 monoclonal antibody, has received approval from Health Canada for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with active disease defined by clinical and imaging features. In clinical trials, active disease was defined as at least one relapse or one Gd-enhancing lesion in the previous year.